213 related articles for article (PubMed ID: 32833434)
1. Effect of Disease-Associated P123H and V70M Mutations on β-Synuclein Fibrillation.
Sharma K; Mehra S; Sawner AS; Markam PS; Panigrahi R; Navalkar A; Chatterjee D; Kumar R; Kadu P; Patel K; Ray S; Kumar A; Maji SK
ACS Chem Neurosci; 2020 Sep; 11(18):2836-2848. PubMed ID: 32833434
[TBL] [Abstract][Full Text] [Related]
2. Dementia with Lewy bodies-associated ß-synuclein mutations V70M and P123H cause mutation-specific neuropathological lesions.
Psol M; Darvas SG; Leite K; Mahajani SU; Bähr M; Kügler S
Hum Mol Genet; 2021 Apr; 30(3-4):247-264. PubMed ID: 33760043
[TBL] [Abstract][Full Text] [Related]
3. Neurotoxic conversion of beta-synuclein: a novel approach to generate a transgenic mouse model of synucleinopathies?
Fujita M; Sekigawa A; Sekiyama K; Sugama S; Hashimoto M
J Neurol; 2009 Aug; 256 Suppl 3():286-92. PubMed ID: 19711118
[TBL] [Abstract][Full Text] [Related]
4. Possible Role of Amyloidogenic Evolvability in Dementia with Lewy Bodies: Insights from Transgenic Mice Expressing P123H β-Synuclein.
Fujita M; Ho G; Takamatsu Y; Wada R; Ikeda K; Hashimoto M
Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32325870
[TBL] [Abstract][Full Text] [Related]
5. Enhanced lysosomal pathology caused by beta-synuclein mutants linked to dementia with Lewy bodies.
Wei J; Fujita M; Nakai M; Waragai M; Watabe K; Akatsu H; Rockenstein E; Masliah E; Hashimoto M
J Biol Chem; 2007 Sep; 282(39):28904-28914. PubMed ID: 17652097
[TBL] [Abstract][Full Text] [Related]
6. Generation and characterization of novel conformation-specific monoclonal antibodies for α-synuclein pathology.
Vaikath NN; Majbour NK; Paleologou KE; Ardah MT; van Dam E; van de Berg WD; Forrest SL; Parkkinen L; Gai WP; Hattori N; Takanashi M; Lee SJ; Mann DM; Imai Y; Halliday GM; Li JY; El-Agnaf OM
Neurobiol Dis; 2015 Jul; 79():81-99. PubMed ID: 25937088
[TBL] [Abstract][Full Text] [Related]
7. FKBP12-immunopositive inclusions in patients with α-synucleinopathies.
Honjo Y; Ayaki T; Horibe T; Ito H; Takahashi R; Kawakami K
Brain Res; 2018 Feb; 1680():39-45. PubMed ID: 29246765
[TBL] [Abstract][Full Text] [Related]
8. Distinct Effects of Familial Parkinson's Disease-Associated Mutations on α-Synuclein Phase Separation and Amyloid Aggregation.
Xu B; Fan F; Liu Y; Liu Y; Zhou L; Yu H
Biomolecules; 2023 Apr; 13(5):. PubMed ID: 37238596
[TBL] [Abstract][Full Text] [Related]
9. Beta-synuclein gene alterations in dementia with Lewy bodies.
Ohtake H; Limprasert P; Fan Y; Onodera O; Kakita A; Takahashi H; Bonner LT; Tsuang DW; Murray IV; Lee VM; Trojanowski JQ; Ishikawa A; Idezuka J; Murata M; Toda T; Bird TD; Leverenz JB; Tsuji S; La Spada AR
Neurology; 2004 Sep; 63(5):805-11. PubMed ID: 15365127
[TBL] [Abstract][Full Text] [Related]
10. Cryo-EM structure of amyloid fibril formed by α-synuclein hereditary A53E mutation reveals a distinct protofilament interface.
Sun C; Zhou K; DePaola P; Shin WS; Hillyer T; Sawaya MR; Zhu R; Peng C; Zhou ZH; Jiang L
J Biol Chem; 2023 Apr; 299(4):104566. PubMed ID: 36871760
[TBL] [Abstract][Full Text] [Related]
11. The loss of inhibitory C-terminal conformations in disease associated P123H β-synuclein.
Janowska MK; Baum J
Protein Sci; 2016 Jan; 25(1):286-94. PubMed ID: 26332674
[TBL] [Abstract][Full Text] [Related]
12. α-Synuclein misfolding and aggregation: Implications in Parkinson's disease pathogenesis.
Mehra S; Sahay S; Maji SK
Biochim Biophys Acta Proteins Proteom; 2019 Oct; 1867(10):890-908. PubMed ID: 30853581
[TBL] [Abstract][Full Text] [Related]
13. A simple, versatile and robust centrifugation-based filtration protocol for the isolation and quantification of α-synuclein monomers, oligomers and fibrils: Towards improving experimental reproducibility in α-synuclein research.
Kumar ST; Donzelli S; Chiki A; Syed MMK; Lashuel HA
J Neurochem; 2020 Apr; 153(1):103-119. PubMed ID: 31925956
[TBL] [Abstract][Full Text] [Related]
14. Accelerated formation of alpha-synuclein oligomers by concerted action of the 20S proteasome and familial Parkinson mutations.
Lewis KA; Yaeger A; DeMartino GN; Thomas PJ
J Bioenerg Biomembr; 2010 Feb; 42(1):85-95. PubMed ID: 20148295
[TBL] [Abstract][Full Text] [Related]
15. The novel Parkinson's disease linked mutation G51D attenuates in vitro aggregation and membrane binding of α-synuclein, and enhances its secretion and nuclear localization in cells.
Fares MB; Ait-Bouziad N; Dikiy I; Mbefo MK; Jovičić A; Kiely A; Holton JL; Lee SJ; Gitler AD; Eliezer D; Lashuel HA
Hum Mol Genet; 2014 Sep; 23(17):4491-509. PubMed ID: 24728187
[TBL] [Abstract][Full Text] [Related]
16. Alteration of Structure and Aggregation of α-Synuclein by Familial Parkinson's Disease Associated Mutations.
Sahay S; Ghosh D; Singh PK; Maji SK
Curr Protein Pept Sci; 2017; 18(7):656-676. PubMed ID: 26972727
[TBL] [Abstract][Full Text] [Related]
17. Neuropathology of synuclein aggregates.
Duda JE; Lee VM; Trojanowski JQ
J Neurosci Res; 2000 Jul; 61(2):121-7. PubMed ID: 10878583
[TBL] [Abstract][Full Text] [Related]
18. Research Progress of α-Synuclein Aggregation Inhibitors for Potential Parkinson's Disease Treatment.
Kalsoom I; Wang Y; Li B; Wen H
Mini Rev Med Chem; 2023; 23(20):1959-1974. PubMed ID: 37198991
[TBL] [Abstract][Full Text] [Related]
19. Structural basis of the interplay between α-synuclein and Tau in regulating pathological amyloid aggregation.
Lu J; Zhang S; Ma X; Jia C; Liu Z; Huang C; Liu C; Li D
J Biol Chem; 2020 May; 295(21):7470-7480. PubMed ID: 32291284
[TBL] [Abstract][Full Text] [Related]
20. Biochemical and morphological classification of disease-associated alpha-synuclein mutants aggregates.
Tanaka G; Yamanaka T; Furukawa Y; Kajimura N; Mitsuoka K; Nukina N
Biochem Biophys Res Commun; 2019 Jan; 508(3):729-734. PubMed ID: 30528390
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
